<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176889</url>
  </required_header>
  <id_info>
    <org_study_id>14PSHS</org_study_id>
    <nct_id>NCT02176889</nct_id>
  </id_info>
  <brief_title>A Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals</brief_title>
  <acronym>14PSHS</acronym>
  <official_title>A Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sabinsa Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Lactospore is safe in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: Lab parameters</measure>
    <time_frame>Over 30 days</time_frame>
    <description>CBC, electrolytes (Na, K, Cl), glucose, creatinine, AST, ALT, GGT, and bilirubin levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability: Anthropometric safety measures</measure>
    <time_frame>Over 30 days</time_frame>
    <description>Blood pressure, Heart Rate, Weight, BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability: Number of Adverse Events</measure>
    <time_frame>Over 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lactospore</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactospore</intervention_name>
    <description>Bacillus coagulans MTCC 5856</description>
    <arm_group_label>Lactospore</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years of age

          -  If female, subject is not of child bearing potential or female subject of childbearing
             potential must agree to use a medically approved method of birth control and have a
             negative urine pregnancy test result.

          -  Healthy as determined by laboratory results and medical history

          -  Normal BMI 18.5 - 29.9 kg/m2

          -  Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial

          -  Subject has any clinically significant medical conditions

          -  Subject requires the use of prescribed medications (other than birth control)

          -  Use of illicit drugs or history of drug or alcohol abuse with the past 5 years
             (currently having more than 2 standard alcoholic drinks per day)

          -  Participation in a clinical research trial within 30 days prior to randomization

          -  Clinically significant abnormal laboratory results at screening

          -  Allergy or sensitivity to test product ingredients

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent

          -  Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures or which may pose significant
             risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lactospore</keyword>
  <keyword>Bacillus coagulans</keyword>
  <keyword>Safety</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

